Mitochondrial Dysfunction and β-Cell Homeostasis
Mitochondrial Regulation of β-Cell Function and Systemic Metabolism
Mitochondrial function is essential for the proper operation of pancreatic β-cells and
insulin-sensitive tissues such as liver,
muscle, and adipose. Pancreatic β-cells possess unique metabolic characteristics, with
glucose-stimulated insulin secretion (GSIS)
being highly dependent on mitochondrial function. As illustrated in Figure 1, this process
relies on a finely tuned network of
mitochondrial metabolism, bioenergetics, and signaling.
Figure 1. Mitochondrial pathways required for insulin secretion[1].
Studies have shown that once mitochondrial dysfunction occurs, it affects multiple aspects of
diabetes pathophysiology, including
impaired glucose homeostasis, increased oxidative stress, and insulin resistance. Collectively,
these disturbances contribute to
metabolic syndrome and its associated complications[2].
Mechanistically, the interplay between energy metabolism and oxidative
stress forms a self-reinforcing positive feedback loop, as illustrated in Figure 2—excessive reactive oxygen species (ROS) production
is both a consequence and a driver of mitochondrial dysfunction, creating a vicious cycle that
is difficult to break. This vicious
cycle amplifies mitochondrial damage, disrupts multiple cellular pathways, and ultimately drives
β-cell dysfunction and systemic
insulin resistance.
Figure 2. The pathway through which mitochondrial dysfunction leads to insulin resistance[2].
The Key Pathways of Mitochondrial Dysfunction-Induced Insulin Resistance
Recent studies have systematically revealed how mitochondrial damage, from molecular to systemic
metabolic levels, disrupts β-cell identity,
function, and survival. Indeed, mitochondrial dysfunction systemically impairs insulin
sensitivity and drives diabetes progression through
the following pathways: energy metabolism disruption, lipid accumulation, oxidative stress,
inflammatory activation, and signaling
inhibition[2].
1. Impaired mitochondrial energy metabolism
● Reduced oxidative phosphorylation (OXPHOS) capacity and ATP
synthesis lead to insufficient cellular energy supply.
● Decreased ATP → increased AMP/ATP ratio → AMPK activation,
which inhibits anabolic processes and disrupts insulin signaling.
2. Defective fatty acid β-oxidation
● Impaired mitochondrial β-oxidation → accumulation of free fatty acids (FFAs) and their
metabolites (e.g., DAG, ceramides).
● DAG activates PKC → inhibits IRS-1 function → blocks insulin signal transduction.
3. Enhanced oxidative stress
● Dysfunctional electron transport chain (ETC) → increased ROS
production.
● Excessive ROS activate stress kinases (e.g., JNK) →
phosphorylate inhibitory serine residues on IRS-1 → suppress insulin signaling.
● ROS also directly oxidize key signaling molecules such as the insulin receptor and Akt, further
impairing insulin sensitivity.
4. Activation of inflammatory signaling
● Mitochondrial damage releases DAMPs (e.g., mtDNA) → activates TLRs and NLRP3 inflammasome →
releases pro-inflammatory cytokines (e.g., TNF-α, IL-6).
● These cytokines inhibit IRS activity via JNK/IKKβ/NF-κB pathways, thereby promoting insulin resistance.
5. Impaired GLUT4 translocation
● Disrupted insulin signaling → reduced Akt activation → impaired GLUT4 translocation to the plasma membrane → decreased glucose uptake →
hyperglycemia.
6. Abnormal mitochondrial dynamics
● Increased mitochondrial fission (upregulated Drp1) and reduced fusion (downregulated Mfn1/2) →
mitochondrial fragmentation → further functional decline, forming a vicious cycle.
7. Decline in autophagy function
● Impaired MQC → damaged mitochondria cannot be cleared → persistent ROS elevation → exacerbated
cellular stress and insulin resistance.
8. Synergistic effects of hyperglycemia and lipotoxicity
● High-glucose and high-lipid conditions increase mitochondrial burden, forming a feedback loop
of “metabolic stress → mitochondrial dysfunction → insulin resistance”.
MQC Mechanisms and Their Role in Metabolic Dysfunction
Given the central role of mitochondria in β-cell function and systemic metabolism, it is
essential to examine mitochondrial quality
control (MQC). MQC acts as a vital defense mechanism for maintaining metabolic homeostasis
by ensuring mitochondrial integrity and
metabolic flexibility. To understand how MQC fulfills these protective roles, it is
necessary to explore the underlying molecular
mechanisms.
MQC Molecular Mechanisms
MQC is a network encompassing biogenesis, dynamics (fission and fusion), and mitophagy.
Impairments in MQC or the mitochondrial
life cycle can lead to defects in mitochondrial structure, gene expression, and energetics,
which in turn disrupt the tightly
regulated processes of mitochondrial genome integrity, replication, biogenesis,
fission/fusion dynamics, and turnover via mitophagy.
Figure 3. MQC mechanisms[3].
To maintain optimal function, mitochondria undergo finely tuned quality control processes,
which involve mitochondrial motility,
mitochondrial-derived vesicles (MDVs), the ubiquitin-proteasome
system, and various cellular environmental factors.
● Mitochondrial biogenesis: Nuclear and mitochondrial DNA coordinate the synthesis of
new mitochondria, regulated by coactivators and transcription factors via membrane protein
import systems.
● Mitochondrial dynamics: Fusion is mediated by outer
mitochondrial membrane (OMM) proteins (MFN1 and MFN2), whereas fission is mediated
by DRP1 and its receptors (Fis1, Mff, Mid49, Mid51).
● Mitophagy: Primarily mediated by the PINK1/Parkin pathway and receptor-mediated
pathways (e.g., BNIP3, NIX, FUNDC1).
● MDV biogenesis: Mitochondria selectively release damaged components or mtDNA via
MDVs, which are subsequently delivered to lysosomes for degradation.
● Mitocytosis: Damaged mitochondria are transported to migrasomes and expelled from
migrating cells.
● Licensed mitophagy: Cells transfer damaged mitochondrial components to neighboring
cells via extracellular vesicles for clearance.
● Mitochondrial transfer: When endogenous biogenesis is insufficient, cells can
acquire healthy mitochondria from neighboring cells.
Metabolic Impact of MQC Dysregulation
Figure 4. A retrograde mitochondrial signaling cascade induces the loss of identity and
maturity in metabolic tissues[4].
Defects in MQC activate a retrograde (mitochondria-to-nucleus) signaling program that
impairs cellular identity and maturity in metabolic tissues,
including β-cells, hepatocytes, and brown adipocytes. Impairments in genome integrity,
mitochondrial dynamics, or turnover disrupt the ETC-OXPHOS
system, activate the mtISR, induce chromatin remodeling, and promote cellular immaturity
rather than apoptosis, ultimately driving metabolic
dysfunction.
Figure 5. MQC imbalance in the pathophysiology of diabetes and its complications[3].
MQC dysregulation triggers retrograde signaling that impairs the identity and maturity of
insulin-sensitive tissues, including the pancreas,
liver, adipose tissue, muscle, retina, heart, and kidney (Figure 5). This disruption
compromises cellular metabolism, energy homeostasis,
and tissue function, ultimately leading to systemic insulin resistance and diabetes
progression. Restoring MQC plasticity in these
tissues offers a strategic intervention to mitigate metabolic dysfunction.
New Directions in Diabetes Therapy: Restoring Mitochondrial Function
Diabetes progression is closely associated with mitochondrial structural and functional
abnormalities. Restoring mitochondrial function
now goes beyond simple “antioxidation” , involving precise interventions that target the
entire MQC life cycle. By modulating mitochondrial
function, it is possible to alleviate insulin resistance and correct metabolic dysregulation
in diabetes, offering new avenues for drug
development. The following summarizes current strategies and related research on
mitochondria-targeted therapies for diabetes[1-5].
Table 1. Enhancing mitochondrial “quantity” — stimulating biogenesis.
Table 2. Enhancing mitochondrial “quality” — regulating dynamics (fusion–fission balance).
Table 3. Clearing damaged mitochondria — activating mitophagy.
Table 4. Reducing oxidative stress — mitochondria-targeted antioxidants.
Table 5. Correcting “mitochondrial overheating” — mild OXPHOS inhibition.
Table 6. Reshaping mitochondria–organelle interactions (MAMs, lipid droplets, sarcoplasmic
reticulum).
Table 7. Next-generation: transplantation, photobiomodulation, immuno-metabolism.
Summary
Mitochondrial dysfunction in pancreatic β-cells impairs insulin secretion and cellular
identity, contributing to systemic metabolic
disturbances and driving diabetes progression. Interventions targeting mitochondrial quality
control (MQC) are evolving from
mechanistic studies toward precision strategies. Mitochondria-targeted approaches—including
enhancing PGC-1α-mediated biogenesis,
correcting Drp1/OPA1 imbalance to restore dynamic homeostasis, or activating
PINK1/Parkin-dependent mitophagy to clear damaged
mitochondria—can interrupt the vicious cycle of “hyperglycemia → ROS → insulin secretion
failure” at different stages. Future
research should focus on combinatorial strategies and precise targeting of MQC nodes to
advance mitochondria-based therapies for diabetes.
Stay Informed with Science Updates
Explore insights tailored to your interests！
Instagram
